- Home
- RDI vs FEMY Comparison
RDI vs FEMY Comparison
Compare RDI & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- FEMY
- Stock Information
- Founded
- RDI 1937
- FEMY 2004
- Country
- RDI United States
- FEMY United States
- Employees
- RDI N/A
- FEMY N/A
- Industry
- RDI Movies/Entertainment
- FEMY Medical/Dental Instruments
- Sector
- RDI Consumer Discretionary
- FEMY Health Care
- Exchange
- RDI Nasdaq
- FEMY Nasdaq
- Market Cap
- RDI 27.9M
- FEMY 29.9M
- IPO Year
- RDI N/A
- FEMY 2021
- Fundamental
- Price
- RDI $1.34
- FEMY $0.94
- Analyst Decision
- RDI Hold
- FEMY Strong Buy
- Analyst Count
- RDI 1
- FEMY 3
- Target Price
- RDI $2.40
- FEMY $8.67
- AVG Volume (30 Days)
- RDI 27.4K
- FEMY 259.3K
- Earning Date
- RDI 08-13-2025
- FEMY 08-07-2025
- Dividend Yield
- RDI N/A
- FEMY N/A
- EPS Growth
- RDI N/A
- FEMY N/A
- EPS
- RDI N/A
- FEMY N/A
- Revenue
- RDI $205,644,000.00
- FEMY $1,699,232.00
- Revenue This Year
- RDI $7.47
- FEMY $283.83
- Revenue Next Year
- RDI $13.22
- FEMY $161.03
- P/E Ratio
- RDI N/A
- FEMY N/A
- Revenue Growth
- RDI N/A
- FEMY 61.97
- 52 Week Low
- RDI $1.17
- FEMY $0.69
- 52 Week High
- RDI $1.89
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- RDI 53.00
- FEMY 50.13
- Support Level
- RDI $1.27
- FEMY $0.91
- Resistance Level
- RDI $1.34
- FEMY $0.99
- Average True Range (ATR)
- RDI 0.06
- FEMY 0.05
- MACD
- RDI 0.01
- FEMY 0.00
- Stochastic Oscillator
- RDI 87.50
- FEMY 28.50
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.